Advertisement
Letter to the Editor| Volume 57, ISSUE 1, P62-63, January 2010

The vascular endothelial growth factor +405 G/C polymorphism in psoriasis

Published:July 12, 2010DOI:https://doi.org/10.1016/j.jdermsci.2009.10.009
The vascular endothelial growth factor +405 G/C polymorphism in psoriasis
Previous ArticleThe H syndrome: Two novel mutations affecting the same amino acid residue of hENT3
Next ArticleConstruction and immune response of HSV–2gD–Hsp70 DNA vaccine
      Psoriasis is a chronic inflammatory disorder of the skin keratinocytes, involving the expansion and dilation of superficial dermal microvasculature. Both genetic and environmental factors have important roles in the development of the disease. Angiogenesis has been indicated as a common and important pathogenic component in psoriasis, and VEGF, being a key contributor to angiogenesis, was further considered. Several studies have demonstrated that VEGF expression levels were increased in the sera of psoriasis patients [
      • Creamer D.
      • Allen M.
      • Jaggar R.
      • Stevens R.
      • Bicknell R.
      • Barker J.
      Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor.
      Arch Dermatol. 2002; 138: 791-796
      ,
      • Young H.S.
      • Summers A.M.
      • Bhushan M.
      • Brenchley P.E.
      • Griffiths C.E.
      Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.
      J Invest Dermatol. 2004; 122: 209-215
      ], and that VEGF serum levels were directly correlated with disease activity [
      • Creamer D.
      • Allen M.
      • Jaggar R.
      • Stevens R.
      • Bicknell R.
      • Barker J.
      Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor.
      Arch Dermatol. 2002; 138: 791-796
      ]. Keratin14-VEGF (VEGF driven by K14 gene promoter) transgenic mice developed inflammatory skin lesion with many cellular and molecular features mimic psoriasis [
      • Xia Y.P.
      • Li B.
      • Hylton D.
      • Detmar M.
      • Yancopoulos G.D.
      • Rudge J.S.
      Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis.
      Blood. 2003; 102: 161-168
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Dermatological Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Creamer D.
        • Allen M.
        • Jaggar R.
        • Stevens R.
        • Bicknell R.
        • Barker J.
        Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor.
        Arch Dermatol. 2002; 138: 791-796
        View in Article
        • Young H.S.
        • Summers A.M.
        • Bhushan M.
        • Brenchley P.E.
        • Griffiths C.E.
        Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.
        J Invest Dermatol. 2004; 122: 209-215
        View in Article
        • Xia Y.P.
        • Li B.
        • Hylton D.
        • Detmar M.
        • Yancopoulos G.D.
        • Rudge J.S.
        Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis.
        Blood. 2003; 102: 161-168
        View in Article
        • Barile S.
        • Medda E.
        • Nistico L.
        • Bordignon V.
        • Cordiali-Fei P.
        • Carducci M.
        • et al.
        Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis.
        Exp Dermatol. 2006; 15: 368-376
        View in Article
        • Butt C.
        • Lim S.
        • Greenwood C.
        • Rahman P.
        VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis.
        BMC Musculoskelet Disord. 2007; 8: 1
        View in Article
        • Wang Z.
        • Liang W.
        • Zhang B.
        • Lv M.
        • Wang J.
        • Zhang L.
        Single nucleotide polymorphisms of VEGF gene and Psoriasis risk.
        J Dermatol Sci. 2008; 49: 263-265
        View in Article
        • Wongpiyabovorn J.
        • Yooyongsatit S.
        • Ruchusatsawat K.
        • Avihingsanon Y.
        • Hirankarn N.
        Association of the CTG (-2578/-460/+405) haplotype within the vascular endothelial growth factor gene with early-onset psoriasis.
        Tissue Antigens. 2008; 72: 458-463
        View in Article
        • Lee J.H.
        • Cho E.Y.
        • Namkung J.H.
        • Kim E.
        • Kim S.
        • Shin E.S.
        • et al.
        Single-nucleotide polymorphisms and haplotypes in the VEGF receptor 3 gene and the haplotype GC in the VEGFA gene are associated with psoriasis in Koreans.
        J Invest Dermatol. 2008; 128: 1599-1603
        View in Article
        • Lenny N.
        • Westendorf J.J.
        • Hiebert S.W.
        Transcriptional regulation during myelopoiesis.
        Mol Biol Rep. 1997; 24: 157-168
        View in Article
        • Stevens A.
        • Soden J.
        • Brenchley P.E.
        • Ralph S.
        • Ray D.W.
        Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter.
        Cancer Res. 2003; 63: 812-816
        View in Article

      Article info

      Publication history

      Published online: July 12, 2010
      Received: July 1, 2009

      Identification

      DOI: https://doi.org/10.1016/j.jdermsci.2009.10.009

      Copyright

      © 2009 Japanese Society for Investigative Dermatology. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX